by
The acute repetitive seizures market consists of intranasal drugs therapy used for treating acute repetitive seizures that frequently occur within a short period of time and last a few minutes. Acute repetitive seizures often arise in patients with epilepsy or status epilepticus. The intranasal drugs are easily administered and rapidly absorbed through nasal tissues providing quick relief from acute seizures.
The global acute repetitive seizures market is estimated to be valued at US$ 7.12 Bn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the acute repetitive seizures market are Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC. Key players Neurelis, Inc. and Bausch Health Companies Inc. hold a major market share with their intranasal diazepam and midazolam therapies.
Acute Repetitive Seizures Market Growth offers opportunities in developing novel therapies such as nasal sprays to reduce administration time and minimally invasive delivery. Companies are focusing on developing therapies with quick onset of action and fewer side effects. Technological advancements in bioavailability and pharmacokinetic enhancements of intranasal drugs are further expanding application in acute repetitive seizures management.
Market Drivers
High incidence and recurrence of refractory status epilepticus presents a large patient pool requiring emergency care. According to World Health Organization, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Increasing research for developing new generation intranasal therapies with enhanced bioavailability and minimal side effects is fostering market growth. Growing healthcare expenditures and improving access to advanced healthcare systems in developing nations also contribute to industry expansion.
Current challenges in Acute Repetitive Seizures Market:
The acute repetitive seizures market is currently facing various challenges which include lack of approved drugs for treatment of acute repetitive seizures condition. The neurological disorders always come with various challenges in development of effective treatment options due to complexities associated with the central nervous system. Other challenges include high attrition rate during clinical trials of drug candidates, need for extensive research activities to understand exact mechanism and cause of the condition. The development of new treatment options also requires huge investments which puts pressure on companies involved. Long approval timelines by regulatory authorities is another challenge being faced in this market.
SWOT Analysis
Strength: Growing research activities by pharmaceutical companies to develop new drug entities for treatment. High unmet needs exist currently providing scope for market growth.
Weakness: Presence of limited approved treatment options currently posing treatment challenges. Understanding exact mechanisms and causes of condition is complex hurdle.
Opportunity: Increasing prevalence of neurological disorders worldwide indicating potential for future demand. Scope for partnerships and collaborations in research and drug development.
Threats: Stringent regulatory pathways for approval of new drugs increases risks in drug development. High R&D costs involved puts pressure on returns on investments. Rising costs of clinical trials also threatens product feasibility.
Geographical regions with high market concentration:
Currently, North America region holds majority share of the overall acute repetitive seizures market in terms of value. Factors such as presence of advanced healthcare facilities, widespread medical insurance, high healthcare expenditure contribute to high market concentration in the region. Europe is another major regional market supported by increasing research funding for development of new treatments.
Fastest growing region:
Asia Pacific region is expected to witness fastest growth over the forecast period in the acute repetitive seizures market. Factors such as rising incidence of neurological disorders, growing healthcare expenditure, expansion of private healthcare sectors, increasing awareness about conditions are supporting market growth in Asia Pacific region. India and China are anticipated to be highly lucrative country markets for acute repetitive seizures over coming years.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
